Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC
The Canadian Cancer Trials Group (CCTG) has launched a Phase 2 study of CFI-400945 in combination with Imfinzi (durvalumab) for the treatment of advanced or metastatic triple negative breast cancer (TNBC). CFI-400945 is an investigational compound that stops cell division by inhibiting a protein called polo-like kinase 4. Because unchecked cell division is a hallmark of cancer cells, blocking it may kill these cells or slow their growth. Imfinzi, developed by AstraZeneca, is a type of immunotherapy called an immune checkpoint inhibitor that prevents a protein called PD-L1 from interacting with the PD-1 receptor in immune cells. Cancer cells often use this interaction to evade immune attacks. “Immunotherapy in combination with chemotherapy has shown promise in this disease; however, non-chemotherapy combinations which avoid those toxicities and may have activity in the chemorefractory setting are of particular interest,” said David Cescon, MD, medical oncologist at Princess Margaret Cancer Centre (PMCC), and Andrew G. Robinson, MD, of Queen’s Uni
Subscribe or to access all post and page content.